Pharmaceuticals

Kedrab Market 2026 expanding with rabies immunoglobulin demand

March 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Kedrab Market During The Forecast Period 2026–2030?

Historical expansion was driven by significant rabies fatality rates, a prevalent reliance on immunoglobulin products, restricted early vaccine access, the implementation of public health emergency protocols, and hospital-centric rabies management.

The anticipated market expansion in the forecast period can be attributed to a rise in animal bite incidents, the broader reach of rabies awareness campaigns, improvements in emergency care infrastructure, enhanced access to monoclonal antibodies, and increased governmental investment in rabies prevention. Significant trends expected during this period involve the growing application of rabies passive immunization, the expansion of post-exposure prophylaxis programs, a heightened focus on zoonotic disease control, an increased demand for emergency immunotherapy, and the strengthening of public health response systems.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20124&type=smp

Which Economic Or Industry Drivers Are Impacting The Kedrab Market?

The growing occurrence of rabies is anticipated to propel the kedrab market in the future. Rabies, a condition almost invariably leading to death from contact with infected animals, presents a significant public health challenge, especially where vaccine availability is scarce. The rise in rabies cases stems from insufficient vaccination of pets, inadequate access to post-exposure preventive treatments, and the presence of rabies in wild animals, particularly in areas lacking sufficient services. Kedrab functions as a human rabies immunoglobulin, offering immediate passive protection to individuals exposed to the rabies virus until active immunity is established via vaccination. As an illustration, data from the South Dakota Department of Health, a US government body, indicated that approximately 20 animals in South Dakota were confirmed rabid in 2023 by April 2024, marking a 122% rise from the 9 instances recorded in 2022. Consequently, the escalating incidence of rabies stimulates the demand for kedrab.

What Market Segments Are Evaluated Within The Kedrab Market?

The kedrab market covered in this report is segmented –

1) By Indication: Post-Exposure Prophylaxis For Rabies, Treatment For Patients Exposed To Suspected Rabid Animals

2) By Formulation: Injectable Formulation, Lyophilized Powder For Reconstitution

3) By Route Of Administration: Intramuscular Injection, Subcutaneous Injection

4) By Distribution Channel: Direct Sales, Wholesalers And Distributors, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals, Emergency Departments, Specialty Clinics, Public Health Organizations

What Industry Trends Are Redefining The Kedrab Market?

Leading firms are active in the kedrab market, prioritizing the creation of novel solutions and obtaining regulatory agreements, including exclusive licensing and distribution continuation notices, to expand kedrab U.S. commercial scope and market footprint. This type of notice serves as a formal declaration from a pharmaceutical or biotechnology entity, signifying the renewal or extension of a current agreement that confers sole rights for the licensing, distribution, or commercialization of a particular product. As an example, in July 2023, Kamada Ltd., an Israel-based company specializing in plasma-derived biopharmaceuticals, disclosed that Kedrion Biopharma had chosen to prolong their exclusive U.S. distribution pact for KEDRAB, a human rabies immune globulin administered for post-exposure prophylaxis. KEDRAB offers prompt passive immunity against rabies after potential exposure, boasting proven efficacy, safety, and regulatory endorsement within the U.S. This two-year extension guarantees ongoing availability and consistent supply, bolstering Kedrion’s commercial distribution framework and strategic position in the U.S. immunoglobulin market, thereby improving patient access and bolstering public health readiness.

Who Are The Top Market Participants Influencing The Kedrab Market?

Major companies operating in the kedrab market are Kamada Ltd., Kedrion Biopharma Inc.

Read the full kedrab market report here:

https://www.thebusinessresearchcompany.com/report/kedrab-global-market-report

What Are The Top-Performing Regions Within The Kedrab Market?

North America was the largest region in the kedrab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the kedrab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Kedrab Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20124&type=smp

Browse Through More Reports Similar to the Global Kedrab Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Online Fashion Retail Market Report 2026

https://www.thebusinessresearchcompany.com/report/online-fashion-retail-global-market-report

Naphthalene Sulfonate Market Report 2026

https://www.thebusinessresearchcompany.com/report/naphthalene-sulfonate-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795